The stock has demonstrated a strong recovery and uptrend over the past six months, rising 43.3% from its low in early November 2025. This performance significantly outpaces the broader market, as evidenced by a 6-month relative strength of 46.1 against the S&P 500. The recent momentum is also positive, with the stock up 33.1% over the last three months and 5.2% over the past month.

Short-term performance shows notable volatility but an overall upward trajectory. The stock price increased from approximately $10.00 at the end of 2025 to a recent high near $14.06 in mid-February 2026, before pulling back. The 1-month gain of 5.2% contrasts with a 5.3% decline in the S&P 500, indicating strong relative strength in the near term.

As of the latest close at $13.31, the stock is positioned in the upper half of its 52-week range of $7.30 to $15.66. The current price represents a recovery of approximately 82% from the 52-week low, but remains about 15% below the 52-week high. No RSI data was provided for a current momentum assessment.

Revenue and profitability have been under pressure. For Q4 2025, revenue was $1.355 billion, representing a year-over-year decline of 6.7%. The company reported a net loss of $96 million for the quarter, with a negative net margin of 4.8%. Gross margin for the quarter was a thin 12.1%, indicating significant cost pressures or pricing challenges.

The company's financial health shows a balanced but leveraged structure, with a debt-to-equity ratio of 0.99. The current ratio of 1.30 suggests adequate short-term liquidity. Cash flow from operations was positive at $76 million for Q4 2025, and the trailing twelve-month free cash flow is $116 million, providing some financial flexibility.

Operational efficiency metrics are weak, reflecting the current downturn. Return on Equity (ROE) is negative at -10%, and Return on Assets (ROA) is -0.062%. The negative ROE, combined with the debt level, indicates the company is not currently generating profits from its equity base.